United We Stand: Regulatory Framework For Biosimilars May Bring Indian And MNCs Closer
This article was originally published in PharmAsia News
Executive Summary
HYDERABAD - Amid numerous fights over patents of leading drug brands, Indian and multinational drug companies may be seeing some sense in working cohesively to help the Indian government establish standard regulations and allow development and launch of future biosimilars and novel biotechnology-based drugs
You may also be interested in...
India’s Biosimilars Guidelines Lay Out Best Practices But Marketed Products Not To Be Reviewed – BIO Conference
The guidelines will enable a standardized biosimilars pathway as opposed to case-by-case application reviews
India’s Biosimilars Guidelines Lay Out Best Practices But Marketed Products Not To Be Reviewed – BIO Conference
The guidelines will enable a standardized biosimilars pathway as opposed to case-by-case application reviews
"We Want To Shape Up Medical Treatment Paradigm Through Partnerships," Says Merck Asia-Pac President Ramesh Subrahmanian: An Interview With PharmAsia News (Part 2 of 2)
Merck Asia Pacific President of Human Health Ramesh Subrahmanian has been among the most energetic executives to have worked in the Indian pharmaceutical industry. Prior to serving in his present responsibilities, Subrahmanian worked for Sanofi-Aventis in several senior capacities - one of which was to head the company's Indian operations in 2000.